Rheumatoid arthritis (update) Committee meeting 6

21/04/2017 Date:

Boardroom, NGC, 180 Great Portland Street, London, W1W 5QZ Location:

Minutes: Confirmed



NICE National Institute for Health and Care Excellence

Committee members present:	
Stephen Ward (SW, Chair)	(Present for notes 1–5)
Ann Bevan (ABe)	(Present for notes 1–5)
Ailsa Bosworth (ABo)	(Present for notes 1–5)
Vicky Chamberlain (VC)	(Present for notes 1–5)
Jennie Jones (JJ)	(Present for notes 1–5)
Frank McKenna (FMK)	(Present for notes 1–5)
Anupama Nandagudi (AN)	(Present for notes 1–5)
Benjamin Parker (BP)	(Present for notes 1–5)
Heidi Siddle (HS)	(Present for notes 1–5)
Louise Warburton (LW)	(Present for notes 1–5)

In attendance:		
Anne-Louise Clayton (AC)	Editor, NICE	(Present for notes 1-4d)
Alex Allen (AA)	Senior Research Fellow, NGC	(Present for notes 1–5)
Serena Carville (SC)	Guideline Lead/Associate Director, NGC	(Present for notes 1–5)
Meredith Faust (MF)	Document Editor/Process Assistant, NGC	(Present for notes 1–5)
Sophia Kemmis-Betty (SKB)	Senior Health Economist, NGC	(Present for notes 1–5)
Jacqui Real (JR)	Senior Research Fellow, NGC	(Present for notes 1–5)
Grit Scheffler-Ansari (GSA)	Research Fellow, NGC	(Present for notes 1–5)

Apologies:	
Joanne Ashe (JA)	Senior Information Scientist, NGC
Caroline Keir (CK)	Guideline Commissioning Manager, NICE

Bruce Kirkham (BK)	Consultant Rheumatologist, Guy's and St Thomas' NHS Foundation Trust
Hilary McKee (HMK)	Consultant Pharmacist, Antrim Area Hospital
Ben Pordes (BPo)	Senior Project Manager, NGC

1. Welcome and objectives for the meeting

The Chair welcomed the committee members and attendees to the sixth meeting on rheumatoid arthritis. The committee members and attendees introduced themselves.

The Chair informed the committee that apologies had been received. These are noted above.

The Chair outlined the objectives of the meeting, which included diagnosing and monitoring ultrasound as well as drafting recommendations.

2. Confirmation of matter under discussion, and declarations of interest

The Chair confirmed that, for the purpose of managing conflicts of interest, the matter under discussion was diagnosing and monitoring ultrasound as well as drafting recommendations.

The Chair asked everyone to declare verbally any interests that have arisen since the last meeting.

Name	Job title, organisation	Declarations of Interest, date declared	Type of interest	Decision taken
Anupama Consultant Nandagudi Rheumatologist, Basildon and Thurrock	IMS-Drug representatives interaction – Market research	Personal, financial, non-specific	Declare and participate	
	University Hospital NHS Trust	M3 Global research – Biologic use – Market research	Personal, financial, non-specific	Declare and participate
		Sermo-Biologic use in RA, psoriatic arthritis and axial spondyloarthropathy – Market research	Personal, financial, non-specific	Declare and participate
Louise Warburton	GP with special interest in Musculoskeletal Medicine, Telford Musculoskeletal Service;	Invited to join a Spondyloarthritis Policy Initiative with Novartis; no remuneration provided.	Personal, non- financial, non-specific	Declare and participate

Associate		
Medical		
Director,		
Shropshire		
Community		
NHS Trust; and		
Senior Lecturer		
in General		
Practice, Keele		
University and		
Musculoskeletal		
Champion		

The Chair and a senior member of the Developer's team noted that the interests declared did not prevent the attendees from fully participating in the meeting.

3. Minutes of last meeting

The Chair asked the committee if it wanted any changes made to the minutes of the last meeting. The committee agreed that the minutes were a true and accurate account of the meeting.

The Chair confirmed that all matters arising had been completed or were in hand.

4. Presentations and discussion

- a) JR presented the drafted recommendations for corticosteroids and prognostic factors. The committee discussed the rationales for recommendations.
- b) SC presented the research recommendation template and advised the committee on research recommendation processes.
- c) GSA presented the evidence for the review question, 'In adults with rheumatoid arthritis, what is the added value of monitoring disease activity with ultrasound?' The committee discussed the evidence.
- d) AA presented the evidence for the review question, 'In adults with suspected inflammatory arthritis (including rheumatoid arthritis), what is the added value of ultrasound in the diagnosis of rheumatoid arthritis?' The committee discussed the evidence.
- e) SKB presented the health economic evidence for both above ultrasound review questions. The committee discussed the evidence and drafted recommendations for each review question.

5. Any other business

The committee discussed the shortened NICE timeline and agreed to the updated meeting calendar.

Date of next meeting:	30/05/2017
Location of next meeting:	Boardroom, National Guideline Centre, 180 Great Portland St, London W1W 5QZ